La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Elevance Health Gestion
Gestion contrôle des critères 3/4
Le PDG Elevance Health's est Gail Boudreaux, nommé en Nov2017, a un mandat de 6.75 ans. La rémunération annuelle totale est $ 21.89M, composée du salaire de 7.3% et des bonus 92.7%, y compris les actions et options de la société. détient directement 0.047% des actions de la société, d'une valeur de $ 59.81M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.3 ans et 11 ans.
Informations clés
Gail Boudreaux
Directeur général
US$21.9m
Rémunération totale
| Pourcentage du salaire du PDG | 7.3% |
| Durée du mandat du directeur général | 6.8yrs |
| Propriété du PDG | 0.05% |
| Durée moyenne d'occupation des postes de direction | 6.5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 11yrs |
Mises à jour récentes de la gestion
Recent updates
Here's Why We Think Elevance Health (NYSE:ELV) Is Well Worth Watching
Aug 02
Elevance Health: Healthcare Services Segment Is Gaining Traction
Jul 31Elevance Health: Buy A Dividend Growth Machine
Jul 18Elevance Health: Favorable Trends Are Emerging (Rating Upgrade)
Jun 28Is Now An Opportune Moment To Examine Elevance Health, Inc. (NYSE:ELV)?
Jun 11Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
May 27We Think Shareholders Will Probably Be Generous With Elevance Health, Inc.'s (NYSE:ELV) CEO Compensation
May 09Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63
Apr 25Elevance Health: It's Not Too Late To Buy Their Dividend Growth
Apr 23Is Elevance Health (NYSE:ELV) Using Too Much Debt?
Apr 16Elevance Health: Not Doing Enough In 2024 To Justify Premium Price
Apr 11Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors
Apr 01Elevance: A Healthy Dose Of Dividend Growth
Mar 21Elevance Heath: Financial Growth And Technical Strength Indicate A Buy
Mar 07Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63
Feb 19Elevance Health: Time To Buy This Incredible Dividend Growth Stock
Jan 26Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement
Jan 19Is Elevance Health (NYSE:ELV) A Risky Investment?
Jan 02Elevance Health, Inc.'s (NYSE:ELV) Shares Not Telling The Full Story
Dec 18A Look At Elevance's Margin Dynamics
Nov 23Is It Time To Consider Buying Elevance Health, Inc. (NYSE:ELV)?
Nov 16Elevance Health: A High Conviction Defensive Blue Chip Buy
Oct 19These 4 Measures Indicate That Elevance Health (NYSE:ELV) Is Using Debt Safely
Oct 04Elevance: Pave The Way For The Next UnitedHealth
Sep 21Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Sep 18Here's The Price I Would Buy Elevance Health Stock
Sep 13If EPS Growth Is Important To You, Elevance Health (NYSE:ELV) Presents An Opportunity
Aug 18Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
Aug 04Narrowing Down High-Quality Dividend Growth: Elevance Health Is Elemental
Jul 24Elevance Health: Beaten Down Share Price Offers Solid Potential
Jul 10Here's Why Elevance Health (NYSE:ELV) Can Manage Its Debt Responsibly
Jul 05Elevance Health: A Critical Update (Rating Downgrade)
Jun 05Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
Jun 04Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
May 05We Think Elevance Health (NYSE:ELV) Can Stay On Top Of Its Debt
Apr 04Elevance Health's (NYSE:ELV) Dividend Will Be Increased To $1.48
Feb 17Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Feb 13Elevance Health: Attractive On Its Expansion Catalysts
Feb 09Elevance Health (NYSE:ELV) Has Announced That It Will Be Increasing Its Dividend To $1.48
Jan 28Elevance Health acquiring Blue Cross and Blue Shield of Louisiana
Jan 23Elevance Health Offers Great Value
Jan 17At US$483, Is Elevance Health Inc. (NYSE:ELV) Worth Looking At Closely?
Jan 17Elevance Health: Strong And Steady EPS Growth Ahead, High Relative Strength Name
Jan 02Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Nov 28Does Elevance Health (NYSE:ELV) Deserve A Spot On Your Watchlist?
Nov 16Elevance Health to acquire speciality pharmacy from CarepathRx
Nov 09Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$7b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$22m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$17m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$5b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$15m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$4b |
| Dec 31 2018 | US$14m | US$1m | US$4b |
| Sep 30 2018 | n/a | n/a | US$5b |
| Jun 30 2018 | n/a | n/a | US$4b |
| Mar 31 2018 | n/a | n/a | US$4b |
| Dec 31 2017 | US$3m | US$162k | US$4b |
Rémunération vs marché: La rémunération totale de Gail ($USD 21.89M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).
Rémunération et revenus: La rémunération de Gail a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Gail Boudreaux (63 yo)
6.8yrs
Titularisation
US$21,889,039
Compensation
Ms. Gail Koziara Boudreaux has been an Independent Director at Target Corporation since September 23, 2021. She has been President, Chief Executive Officer and Director of Elevance Health Inc. (formerly kn...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 6.8yrs | US$21.89m | 0.047% $ 59.8m | |
| Executive VP & CFO | less than a year | US$12.36m | pas de données | |
| Executive VP and Chief Legal & Administrative Officer | 3.8yrs | US$8.11m | 0.0044% $ 5.6m | |
| Executive VP and President of Carelon & CarelonRx | 10.2yrs | US$6.98m | 0.0063% $ 7.9m | |
| Executive VP & President of Government Health Benefits | 6.2yrs | US$6.48m | 0.0098% $ 12.3m | |
| SVP, Treasurer & Chief Investment Officer | 6.3yrs | pas de données | pas de données | |
| Senior VP | 8.8yrs | pas de données | 0.00057% $ 718.2k | |
| Vice President of Investor Relations | no data | pas de données | pas de données | |
| Senior Vice President of Public Affairs | 10.8yrs | pas de données | pas de données | |
| Chief Strategy Officer & Interim Chief Marketing Officer | less than a year | pas de données | pas de données | |
| Executive VP and President of Commercial & Specialty Health Benefits | no data | pas de données | 0.0050% $ 6.3m | |
| President of Dental Business | 7.8yrs | pas de données | pas de données |
6.5yrs
Durée moyenne de l'emploi
58yo
Âge moyen
Gestion expérimentée: L'équipe de direction de ELV est chevronnée et expérimentée (ancienneté moyenne 6.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 6.8yrs | US$21.89m | 0.047% $ 59.8m | |
| Independent Director | 19.8yrs | US$386.76k | 0.0024% $ 3.0m | |
| Independent Chair of the Board | 10.8yrs | US$597.83k | pas de données | |
| Independent Director | 11.1yrs | US$362.53k | pas de données | |
| Independent Director | 6.5yrs | US$371.42k | pas de données | |
| Independent Director | 10.3yrs | US$371.42k | pas de données | |
| Independent Director | 4.8yrs | US$347.28k | 0.0013% $ 1.6m | |
| Independent Director | 13.1yrs | US$360.34k | 0.0031% $ 3.9m | |
| Member of Advisory Board | 11yrs | pas de données | pas de données | |
| Member of Advisory Board | 11yrs | pas de données | pas de données | |
| Member of Advisory Board | 11yrs | pas de données | pas de données | |
| Member of Advisory Board | 11yrs | pas de données | pas de données |
11.0yrs
Durée moyenne de l'emploi
68yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration ELV sont chevronnés et expérimentés (durée moyenne d'administration 11 ans).